{"id":14569,"date":"2023-08-30T01:18:00","date_gmt":"2023-08-29T17:18:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14569"},"modified":"2024-11-24T01:23:42","modified_gmt":"2024-11-23T17:23:42","slug":"kangpu-biopharmaceuticals-secures-series-b-funding-to-advance-molecular-glue-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14569","title":{"rendered":"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies"},"content":{"rendered":"\n

Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will be utilized to accelerate Kangpu’s clinical development of molecular glue protein ubiquitination degradation products and to support early-stage pipeline research.<\/p>\n\n\n\n

Investment in Next-Generation Molecular Glue Technologies<\/strong>
Kangpu Biopharma is known for its new-generation molecular glue protein ubiquitination and protein degradation technologies, including NeoMIDES, SelPDEiS, and X-SYNERGY. These innovative technologies aim to revolutionize the treatment of various diseases through targeted protein degradation.<\/p>\n\n\n\n

Clinical Progress and Upcoming Studies<\/strong>
The company recently completed enrollment in a Phase IIa clinical study for its product candidate KPG-818, which targets systemic lupus erythematosus in the US. In addition, KPG-121 is anticipated to initiate a global multi-center Phase II\/III regulatory study for metastatic castration-resistant prostate cancer in the US shortly. These developments highlight Kangpu Biopharma’s commitment to advancing novel therapies for unmet medical needs.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,2299,70],"class_list":["post-14569","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finance","tag-kangpu-biopharmaceuticals","tag-tpd"],"yoast_head":"\nKangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will be utilized to accelerate Kangpu's clinical development of molecular glue protein ubiquitination degradation products and to support early-stage pipeline research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14569\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14569\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-29T17:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-23T17:23:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14569#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14569\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies\",\"datePublished\":\"2023-08-29T17:18:00+00:00\",\"dateModified\":\"2024-11-23T17:23:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14569\"},\"wordCount\":193,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Kangpu Biopharmaceuticals\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14569#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14569\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14569\",\"name\":\"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-29T17:18:00+00:00\",\"dateModified\":\"2024-11-23T17:23:42+00:00\",\"description\":\"Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will be utilized to accelerate Kangpu's clinical development of molecular glue protein ubiquitination degradation products and to support early-stage pipeline research.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14569#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14569\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14569#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies - Insight, China's Pharmaceutical Industry","description":"Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will be utilized to accelerate Kangpu's clinical development of molecular glue protein ubiquitination degradation products and to support early-stage pipeline research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14569","og_locale":"en_US","og_type":"article","og_title":"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14569","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-29T17:18:00+00:00","article_modified_time":"2024-11-23T17:23:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14569#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14569"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies","datePublished":"2023-08-29T17:18:00+00:00","dateModified":"2024-11-23T17:23:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14569"},"wordCount":193,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Kangpu Biopharmaceuticals","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14569#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14569","url":"https:\/\/flcube.com\/?p=14569","name":"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-29T17:18:00+00:00","dateModified":"2024-11-23T17:23:42+00:00","description":"Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will be utilized to accelerate Kangpu's clinical development of molecular glue protein ubiquitination degradation products and to support early-stage pipeline research.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14569#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14569"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14569#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14569"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14569\/revisions"}],"predecessor-version":[{"id":14571,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14569\/revisions\/14571"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}